Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Scientists at St. Jude Children’s Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer. A phase 1 trial that combined the drug candidate with Avastin reported a ...

HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully ...

Researchers from Mustbio Co. Ltd. and Chung-Ang University have presented the discovery and preclinical characterization of MB-2033, a novel bispecific fusion protein being developed for the treatment ...

Formation of fusion proteins. New genes are formed of two originally independent genes by chromosomal rearrangements, including translocations, insertions, deletions, duplications, and inversions.